Impact of Biologic Therapy on the Small Airways Asthma Phenotype.

Lung · 2022 · PMC9675679 · PMID 36239786

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a borderline significant trendno p-value reported

In a phase 3 randomised controlled trial (RCT) ( n = 205) [ 38 ], there was a borderline significant trend for iv reslizumab 3 mg/kg to improve FEF 25–75 over 16 weeks by 0.233 L/s vs placebo, exceeding the established biological variability in severe asthma of 0.21 L/s [ 39 ] to infer a clinically relevant treatment effect.

also in 231 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.